Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
Acute myeloid leukemia (AML) is a heterogeneous clonal myeloid neoplasm where abnormal
proliferation and impaired differentiation of hematopoietic stem and myeloid progenitor cells
impedes normal hematopoiesis. Sulfasalazine (SSZ) is a broadly available, well tolerated
anti-inflammatory medicine approved for the treatment of ulcerative colitis and rheumatoid
arthritis. Intact SSZ, but not its metabolites 5-aminosalicylic acid and sulfapyridine,
competitively inhibits xCT.21 SSZ is thus an ideal candidate for drug repurposing in AML.The
purpose of this phase I study is to evaluate the safety and feasibility of such strategy,
provide preliminary signals of efficacy, and identify potential biomarkers